Edouard Alphandéry

Dr. Edouard Alphandéry

1. Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Sorbonne Universités, 75005 Paris, France.
+1
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2011 in ACS Nano
Verified
Journal Article
Closed access
Edouard AlphandéryEdouard Alphandéry
Edouard Alphandéry
SFStéphanie Faure
Stéphanie Faure
OSOlivier Seksek
Olivier Seksek
FGFrançois Guyot
François Guyot
ICImène Chebbi
Imène Chebbi

1 January 2020 in Drug Discovery Today
Verified
Journal Article
Closed access
Edouard AlphandéryEdouard Alphandéry
Edouard Alphandéry


11 September 2013 in International Journal of Hyperthermia
Verified
Journal Article
Closed access
Edouard AlphandéryEdouard Alphandéry
Edouard Alphandéry
ICImène Chebbi
Imène Chebbi
FGFrançois Guyot
François Guyot
MDMickaël Durand-Dubief
Mickaël Durand-Dubief
We review the most recent and significant results published in the field of magnetotactic bacteria (MTB), in particular data relating to the use of bacterial magnetosomes in magnetic hyperthermia for the treatment of tumours. We review different methods for cultivating MTB and preparing suspensions of bacterial magnetosomes. As well as the production of magnetosomes, we also review key data on the toxicity of the magnetosomes as well as their heating and anti-tumour efficiencies. The toxicity and efficiency of magnetosomes needs to be understood and the risk-benefit ratio with which to evaluate their use in the magnetic hyperthermia treatment of tumours needs to be measured.

1 January 2017 in Theranostics
Verified
Journal Article
Open access
RFRaphaël Le Fèvre
Raphaël Le Fèvre
MDMickaël Durand-Dubief
Mickaël Durand-Dubief
ICImène Chebbi
Imène Chebbi
CMChalani Mandawala
Chalani Mandawala
FLFrance Lagroix
France Lagroix
Edouard AlphandéryEdouard Alphandéry
Edouard Alphandéry
In this study, biologically synthesized iron oxide nanoparticles, called magnetosomes, are made fully biocompatible by removing potentially toxic organic bacterial residues such as endotoxins at magnetosome mineral core surfaces and by coating such surface with poly-L-lysine, leading to magnetosomes-poly-L-lysine (M-PLL). M-PLL antitumor efficacy is compared with that of chemically synthesized iron oxide nanoparticles (IONPs) currently used for magnetic hyperthermia. M-PLL and IONPs are tested for the treatment of glioblastoma, a dreadful cancer, in which intratumor nanoparticle administration is clinically relevant, using a mouse allograft model of murine glioma (GL-261 cell line). A magnetic hyperthermia treatment protocol is proposed, in which 25 µg in iron of nanoparticles per mm3 of tumor are administered and exposed to 11 to 15 magnetic sessions during which an alternating magnetic field of 198 kHz and 11 to 31 mT is applied for 30 minutes to attempt reaching temperatures of 43-46 °C. M-PLL are characterized by a larger specific absorption rate (SAR of 40 W/gFe compared to 26 W/gFe for IONPs as measured during the first magnetic session), a lower strength of the applied magnetic field required for reaching a target temperature of 43-46 °C (11 to 27 mT compared with 22 to 31 mT for IONPs), a lower number of mice re-administered (4 compared to 6 for IONPs), a longer residence time within tumours (5 days compared to 1 day for IONPs), and a less scattered distribution in the tumour. M-PLL lead to higher antitumor efficacy with full tumor disappearances achieved in 50% of mice compared to 20% for IONPs. This is ascribed to better ability of M-PLL, at equal iron concentrations, to maintain tumor temperatures at 43-46°C over a longer period of times.

2 April 2019 in Nanotoxicology
Verified
Journal Article
Closed access
Edouard AlphandéryEdouard Alphandéry
Edouard Alphandéry
IONP (iron oxide nanoparticles) commercialized for treatments of iron anemia or cancer diseases can be administered at doses exceeding 1 g per patient, indicating their bio-compatibility when they are prepared in the right conditions. Various parameters influence IONP biodistribution such as nanoparticle size, hydrophobicity/hydrophilicity, surface charge, core composition, coating properties, route of administration, quantity administered, and opsonization. IONP biodistribution trends include their capture by the reticuloendothelial system (RES), accumulation in liver and spleen, leading to nanoparticle degradation by macrophages and liver Kupffer cells, possibly followed by excretion in feces. To result in efficient tumor treatment, IONP need to reach the tumor in a sufficiently large quantity, using: (i) passive targeting, i.e. the extravasation of IONP through the blood vessel irrigating the tumor, (ii) molecular targeting achieved by a ligand bound to IONP specifically recognizing a cell receptor, and (iii) magnetic targeting in which a magnetic field gradient guides IONP towards the tumor. As a whole, targeting efficacy is relatively similar for different targeting, yielding a percentage of injected IONP in the tumor of 5.10−4% to 3%, 0.1% to 7%, and 5.10−3% to 2.6% for passive, molecular, and magnetic targeting, respectively. For the treatment of iron anemia disease, IONP are captured by the RES, and dissolved into free iron, which is then made available for the organism. For the treatment of cancer, IONP either deliver chemotherapeutic drugs to tumors, produce localized heat under the application of an alternating magnetic field or a laser, or activate in a controlled manner a sono-sensitizer following ultrasound treatment.